When the TNFα-deficient mice were given the combination treatment, tumor growth was delayed compared to the control mice, and the median survival was 74 days vs. 100 days in mice without the TNFα blockade, confirming the key role of TNFα in the antitumor effect of the combination therapy (ASTX660 + radiation). The gene discussed is TNF; the disease is neoplasm.